<DOC>
	<DOC>NCT00984880</DOC>
	<brief_summary>The primary purpose of this study is to assess the safety and tolerability of AZD3043 following administration of single ascending bolus doses (Part A) and single ascending bolus doses followed by infusion (Part B).</brief_summary>
	<brief_title>Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043</brief_title>
	<detailed_description />
	<criteria>Subjects with suitable veins for cannulation or repeated venepuncture Predose assessment judged without remarks by the investigator Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg Abnormal vital signs, after 15 minutes supine rest, defined as any of the following: Systolic blood pressure &gt;140 mm Hg Diastolic blood pressure &gt;90 mm Hg Heart rate â‰¤45 or &gt;85 beats per minute Lack of normal phenotype for BuChE (Butyrylcholinesterase)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Sedation</keyword>
	<keyword>anaesthesia</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>